Hsiao P-J, Lin H-W, Sung C-C, Wang C-W, Chu P, Lin S-H
Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Clin Nephrol. 2010 Sep;74(3):217-22. doi: 10.5414/cnp74217.
Lercanidipine, a novel dihydropyridine calcium channel antagonist, has been reported to cause sterile cloudy effluent in patients on continuous ambulatory peritoneal dialysis (CAPD). The purpose of the study was to evaluate the incidence and clinical course of cloudy effluent associated with lercanidipine in uremic patients on CAPD.
We designed a consecutive observation study in 40 non-diabetic uremic patients on CAPD treated with lercanidipine 5 mg daily. Lercanidipine-induced cloudy effluent was defined as acellular and culture-negative effluent associated with the use of this drug and exclusion of other causative factors. Time to develop cloudy effluent, dwell effluent amount and the associated symptoms were recorded. Baseline peritoneal membrane characteristics, net ultrafiltration per session and routine biochemistry in serum and dialysate were compared between patients with and without the development of cloudy effluent.
9 patients (22.5%) developed cloudy effluent within 2 days of lercanidipine initiation. The triglyceride concentration in cloudy effluent was greater than 10 mg/dl (19.3 ± 6.3 mg/dl). There was a significant increase in dwell effluent amount (93.3 ± 64 ml/exchange, p < 0.05). Clinical symptoms as abdominal cramping or fullness were observed in 3 patients. All cloudy effluent disappeared after ceasing lercanidipine but recurred after resumption of lercanidipine. Baseline dialysate to plasma (D/P) creatinine ratio (0.7 ± 0.1 vs. 0.51 ± 0.1; p = 0.07) tended to be higher and dialysate total protein (93.4 ± 33 vs. 61.5 ± 24 mg/dl; p < 0.05) were significantly higher in patients with than without the development of cloudy effluent.
The incidence of lercanidipine-associated cloudy effluent is relatively higher with transient benign clinical symptoms. Patients with lercanidipine associated cloudy effluent tend to have a higher membrane transport with an increased effluent amount.
乐卡地平是一种新型二氢吡啶类钙通道拮抗剂,据报道,接受持续性非卧床腹膜透析(CAPD)的患者使用该药后会出现无菌性浑浊透析液。本研究旨在评估接受CAPD的尿毒症患者中与乐卡地平相关的浑浊透析液的发生率及临床病程。
我们设计了一项连续观察研究,纳入40例接受CAPD治疗的非糖尿病尿毒症患者,每日服用5 mg乐卡地平。乐卡地平诱发的浑浊透析液定义为与使用该药相关且排除其他致病因素的无细胞且培养阴性的透析液。记录出现浑浊透析液的时间、留存透析液量及相关症状。比较出现和未出现浑浊透析液的患者的基线腹膜特性、每次透析的净超滤量以及血清和透析液中的常规生化指标。
9例患者(22.5%)在开始使用乐卡地平后2天内出现浑浊透析液。浑浊透析液中的甘油三酯浓度大于10 mg/dl(19.3±6.3 mg/dl)。留存透析液量显著增加(93.3±64 ml/次交换,p<0.05)。3例患者出现腹部绞痛或饱胀等临床症状。停用乐卡地平后,所有浑浊透析液均消失,但重新使用乐卡地平后又复发。出现浑浊透析液的患者的基线透析液与血浆(D/P)肌酐比值(0.7±0.1对0.51±0.1;p = 0.07)倾向于更高,透析液总蛋白(93.